Grifols Reports Q3 2026 Financial Results

Grifols reported Q3 2026 revenue growth of 8.4% at constant currency and a 27.9% increase in net profit. Nine-month free cash flow improved by €110 million year over year, and the leverage ratio fell to 3.98x. Growth in immunoglobulin products supported results, while conditions in China’s albumin market remained a headwind. Management reaffirmed its full-year 2026 financial guidance.